Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00120185 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy of Using Interleukin-2 in Antiretroviral Naïve HIV Patients (ANRS119)

StatusCompleted
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. 2 versions Re-verified since Dec 21, 2011, no change to tracked fieldsv7-v8
  2. Trial status: Terminated to Completed
    • Primary completion date: Nov 2006
    • Study title expanded, about 1 word
    v6
  3. Trial status: Active, Not Recruiting to Terminated
    • Study completion date: Nov 2006
    v5
  4. Re-verified, no change to tracked fieldsv4
  5. Study Identification, Study Statusv3
  6. Re-verified, no change to tracked fieldsv2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Interleukin-2 (IL-2) increases the number of CD4 cells in HIV-1 infected patients under highly active antiretroviral therapy (HAART) with a CD4 cell count over 200/mm3, but its activity in patients without antiretroviral therapy is unknown. This study will test the efficacy and safety of IL-2 in naïve patients with a CD4 count between 300 and 500/m3.
Trial Details
NCT Number NCT00120185
Lead Sponsor French National Agency for Research on AIDS and Viral Hepatitis
Collaborators: Chiron Corporation
Conditions
(from sponsor)		 HIV Infections
Related terms HIV Infections
Enrollment 130 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov